Home > Newsletters > FDAnews Drug Daily Bulletin > Titan Files NDA for Slow-Release Anti-Opioid Probuphine
FDAnews Drug Daily Bulletin
Nov. 8, 2012 | Vol. 9 No. 220
Titan Files NDA for Slow-Release Anti-Opioid Probuphine
Titan Pharmaceutical has submitted an NDA seeking priority review of its Probuphine subcutaneous implant to treat adult opioid dependence. The product is designed to deliver buprenorphine HCl in a span of six months to reduce patients’ use of illicit drug. It uses the company’s ProNeura technology, a solid rod made from a mixture of ethylene-vinyl acetate and the drug substance.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.